Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans.

Isabel PielAnna EngelenDieter LangSimone I SchulzMichael GerischChristine BraseWiebke JanssenLukas FiebigStefan HeitmeierFriederike Kanefendt

Published in: European journal of drug metabolism and pharmacokinetics (2023)

Similar to preclinical experiments, total asundexian-derived radioactivity is cleared quantitatively predominantly via feces. Excretion occurs mainly via amide hydrolysis and as the unchanged drug.

Keyphrases

cell therapy
anaerobic digestion
african american
adverse drug
stem cells
drug induced
emergency department
mesenchymal stem cells
bone marrow